

DAFTAR PUSTAKA

- Adiputra, I. M. S., Trisnadewi, N. W., Oktaviani, N. P. W., Munthe, S. A., Hulu, V. T., Budiastutik, I., Faridi, A., Ramdany, R., Fitriani, R. J., Tania, P. O. A., Rahmiati, B. F., Lusiana, S. A., Susilawaty, A., Sianturi, E., & Suryana. (2021). Metodologi Penelitian Kesehatan. In J. Simarmata & R. Watrianthos (Eds.), *Metodologi Penelitian Kesehatan* (Vol. 3). Yayasan Kita Menulis. https://www.google.co.id/books/edition/Metodologi_Penelitian_Kesehatan/DYtEAAAQBAJ?hl=id&gbpv=0
- Ai, J., Zhang, H., Xu, T., Wu, J., Zhu, M., & Yu, Y. (2020). *Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China Authors.*
- Aidah, S. N. (2021). *Bacaan Wajib! Vaksin Corona.* KBM Indonesia.
- Al Amin, M., & Juniati, D. (2017). Klasifikasi Kelompok Umur Manusia Berdasarkan Analisis Dimensi. *Jurnal Ilmiah Matematika*, 2(6), 1–10.
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R. (2021). Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *New England Journal of Medicine*, 385(24), 2241–2251. <https://doi.org/10.1056/nejmoa2109522>
- Anand, P., & Stahel, V. P. (2021). Review the Safety of COVID-19 mRNA Vaccines: a Review. *Patient Safety in Surgery*, 15(1), 1–9. <https://doi.org/10.1186/s13037-021-00291-9>
- Anderson, E. J., Roupheal, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A. B., Flach, B., Lin, B. C., Doria-Rose, N. A., O'Dell, S., Schmidt, S. D., Corbett, K. S., Swanson, P. A., Padilla, M., ... Beigel, J. H. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine*, 383(25), 2427–2438. <https://doi.org/10.1056/nejmoa2028436>
- Anderson, R. M., Vegvari, C., Truscott, J., & Collyer, B. S. (2020). Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. *The Lancet*, 396(10263), 1614–1616. [https://doi.org/10.1016/S0140-6736\(20\)32318-7](https://doi.org/10.1016/S0140-6736(20)32318-7)
- Antara. (2021). *Komnas Sebut KIPI Akibat Vaksin COVID-19 Paling Banyak Non-Serius.* Antara. <https://m.antaranews.com/berita/2555945/komnas-sebut-kipi-akibat-vaksin-covid-19-paling-banyak-nonserius>
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert,

- D., Spector, S. A., Roupael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., ... Zaks, T. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, 384(5), 403–416. <https://doi.org/10.1056/nejmoa2035389>
- Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021). Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? *Frontiers in Physiology*, 11(January), 1–23. <https://doi.org/10.3389/fphys.2020.571416>
- Banjarnahor, S. (2020). Variasi Gejala COVID-19 yang dialami Perawat Murni Teguh Memorial Hospital. *Indonesian Trust Health Journal*, 3(2).
- Bates, T. A., McBride, S. K., Leier, H. C., Guzman, G., Lyski, Z. L., Schoen, D., Winders, B., Lee, J. Y., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. G. (2022). Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. In *Science Immunology* (Vol. 7, Issue 68). <https://doi.org/10.1126/sciimmunol.abn8014>
- Bati, S., Burucu, R., Cantekin, I., & Donmez, H. (2021). Determining The Side Effects Of COVID-19 (Sinovac) Vaccination On Nurses; An Independent Descriptive Study. *Konuralp Tip Dergisi*, 19, 479–487. <https://doi.org/10.18521/ktd.981790>
- BCCDC. (2022). *British Columbia Report Adverse Events Following Immunization with COVID-19 Vaccines*.
- Bigdelou, B., Sepand, M. R., Najafikhoshnoo, S., Negrete, J. A. T., Sharaf, M., Ho, J. Q., Sullivan, I., Chauhan, P., Etter, M., Shekarian, T., Liang, O., Hutter, G., Esfandiarpour, R., & Zanganeh, S. (2022). COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. *Frontiers in Immunology*, 13(May), 1–16. <https://doi.org/10.3389/fimmu.2022.890517>
- Callender, L. A., Curran, M., Bates, S. M., Mairesse, M., Weigandt, J., & Betts, C. J. (2020). The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. *Frontiers in Immunology*, 11(August), 1–16. <https://doi.org/10.3389/fimmu.2020.01991>
- CDC. (2021). *Moderna COVID-19 Vaccine (also known as Spikevax) Overview and Safety*. Centers of Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html>
- CDC. (2022a). *COVID-19 Moderna COVID-19 Vaccine Overview and Safety Moderna COVID-19 Vaccine Ingredients*. Centers of Disease Control and

Prevention. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html?s_cid=qr2021

CDC. (2022b). *Possible Side Effects After Getting a COVID-19 Vaccine*. Centers of Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html>

Chu, L., Mcphee, R., Huang, W., Bennett, H., Pajon, R., Nestorova, B., Leav, B., & Group, S. (2020). A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine*, 39(January), 2791–2799.

Clothier, H. J., Lawrie, J., Lewis, G., Russell, M., Crawford, N. W., & Buttery, J. P. (2020). SAEFVIC: Surveillance of Adverse Events Following Immunisation (AEFI) in Victoria, Australia, 2018. *Communicable Diseases Intelligence (2018)*, 44. <https://doi.org/10.33321/cdi.2020.44.46>

Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. *Acta Biomedica*, 91(1), 157–160. <https://doi.org/10.23750/abm.v91i1.9397>

Dai, N. F. (2021). Vaksinasi. In Risnawati (Ed.), *Kilas Balik 1 Tahun Bersama Pandemi COVID-19*. Media Sains Indonesia.

Dai, S. P., Zhao, X., & Wu, J. hui. (2021). Effects of Comorbidities on the Elderly Patients with COVID-19: Clinical Characteristics of Elderly Patients Infected with COVID-19 from Sichuan, China. *Journal of Nutrition, Health and Aging*, 25(1), 18–24. <https://doi.org/10.1007/s12603-020-1486-1>

Delila, D. (2021). *PERBEDAAN TINGKAT DEATH ANXIETY ANTARA PASIEN COVID-19, PENYINTAS COVID-19, DAN ANGGOTA MASYARAKAT YANG BELUM PERNAH TERINFEKSI COVID-19*. Universitas Sumatera Utara.

Denly, L. (2021). The Effect of Sex on Responses to Influenza Vaccines. *Human Vaccines and Immunotherapeutics*, 17(5), 1396–1402. <https://doi.org/10.1080/21645515.2020.1830685>

Desnita, R., Sapardi, V. S., & Surya, D. O. (2022). *Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 Dosis Pertama dan Kedua*. 6(1), 20–26.

Dey, A., Wang, H., Quinn, H., Pillsbury, A., Glover, C., Hickie, M., Wood, N., Beard, F., & Macartney, K. (2021). Surveillance of adverse events following immunisation in Australia annual report, 2019. *Communicable Diseases Intelligence (2018)*, 45. <https://doi.org/10.33321/cdi.2021.45.23>

Di Resta, C., Ferrari, D., Viganò, M., Moro, M., Sabetta, E., Minerva, M., Ambrosio, A., Locatelli, M., & Tomaiuolo, R. (2021). The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination an analysis of serological response and side effects. *Vaccines*, 9(5), 1–13.

<https://doi.org/10.3390/vaccines9050522>

- Elviani, R., Anwar, C., & Januar Sitorus, R. (2021). Gambaran Usia Pada Kejadian Covid-19. *JAMBI MEDICAL JOURNAL “Jurnal Kedokteran Dan Kesehatan,”* 9(1), 204–209. <https://doi.org/10.22437/jmj.v9i1.11263>
- Ernawati, A. (2021). Tinjauan Kasus COVID-19 Berdasarkan Jenis Kelamin, Golongan Usia, dan Kepadatan Penduduk di Kabupaten Pati. *Jurnal Litbang: Media Informasi Penelitian, Pengembangan Dan IPTEK,* 17(2), 131–146. <https://doi.org/10.33658/jl.v17i2.280>
- FDA. (2020). The Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). *U.S. Food and Drug Administration (FDA), 2019,* 1–22. <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>
- FDA. (2021). *Moderna COVID-19 Vaccine: Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum* (Vol. 2019). <https://www.fda.gov/media/146338/download>
- Fentia, L. (2020). *Faktor Risiko Gizi Kurang pada Anak Usia 1-5 Tahun dari Keluarga Miskin.* NEM.
- Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H., & Alter, G. (2019). Sex Differences in Vaccine-Induced Humoral Immunity. *Seminars in Immunopathology,* 41(2), 239–249. <https://doi.org/10.1007/s00281-018-0726-5>
- Fung, M., & Babik, J. M. (2021). COVID-19 in Immunocompromised Hosts: What We Know so Far. *Clinical Infectious Diseases,* 72(2), 340–350. <https://doi.org/10.1093/cid/ciaa863>
- Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., Sigal, A., Schmidt, A. G., Iafrate, A. J., Naranbhai, V., & Balazs, A. B. (2021). Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity. *Cell,* 184(9), 2372-2383.e9. <https://doi.org/10.1016/j.cell.2021.03.013>
- Green, M. S., Peer, V., Magid, A., Hagani, N., Anis, E., & Nitzan, D. (2022). Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. *Vaccines,* 10(2), 1–12. <https://doi.org/10.3390/vaccines10020233>
- Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., ... Zhong, N. (2020). Clinical Characteristics of

Coronavirus Disease 2019 in China. *New England Journal of Medicine*, 382(18), 1708–1720. <https://doi.org/10.1056/nejmoa2002032>

Hafizzanovian, H., Oktariana, D., Apriansyah, M. A., & Yuniza, Y. (2021). Peluang Terjadinya Immunization Stress-Related Response (Isrr) Selama Program Vaksinasi Covid-19. *Jurnal Kedokteran Dan Kesehatan Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*, 8(3), 211–222. <https://doi.org/10.32539/jkk.v8i3.13807>

Harris, T., Nair, J., Fediurek, J., & Deeks, S. L. (2017). Assessment of Sex-Specific Differences in Adverse Events Following Immunization Reporting in Ontario, 2012–15. *Vaccine*, 35(19), 2600–2604. <https://doi.org/10.1016/j.vaccine.2017.03.035>

Hartley, G. E., Edwards, E. S. J., Aui, P. M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A. Y., Boo, I., Drummer, H. E., Mark Hogarth, P., O’Hehir, R. E., & Van Zelm, M. C. (2020). Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. In *Science Immunology* (Vol. 5, Issue 54). <https://doi.org/10.1126/sciimmunol.abf8891>

Haruna, S. R., Ponseng, N. A., Rahmadani, S., Rosnania, Afrida, & Bubun, J. (2021). *Kepatuhan Masyarakat dalam Penggunaan Masker sebagai Salah Satu Upaya Pencegahan COVID-19*. Uwais Inspirasi Indonesia.

Hasan, L. (2021). *Hubungan Vaksin COVID-19 dengan Efek Samping yang Ditimbulkan pada Individu di Rumah Sakit Royal Prima Marelana Medan*. Universitas Sumatera Utara.

Hasibuan, M. T. D., & Silaen, H. (2022). *Pencegahan dan Pengendalian Infeksi COVID-19 dalam Mempertahankan Status Kesehatan pada Tenaga Kesehatan di Rumah Sakit*. CV Jejak.

Hatmal, M. M., Al-Hatamleh, M. A. I., Olaimat, A. N., Hatmal, M., Alhaj-Qasem, D. M., Olaimat, T. M., & Mohamud, R. (2021). Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. *Vaccines*, 9(6), 1–23. <https://doi.org/10.3390/vaccines9060556>

Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Da Silva, F. T. (2019). The How’s and What’s of Vaccine Reactogenicity. *Npj Vaccines*, 4(1). <https://doi.org/10.1038/s41541-019-0132-6>

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease

Inhibitor. *Cell*, 181(2), 271-280.e8.
<https://doi.org/10.1016/J.CELL.2020.02.052>

HR, S., & Rantisari, A. M. D. (2021). *Statistik dan Metodologi Penelitian* (Edisi 2). KBM Indonesia.

Immanuel, J. P., Litanto, V., Sanjaya, A., & Rachman, A. F. (2022). Vaksin Pencegahan COVID-19. In J. Jo, S. N. A. Chirsty, D. Matahari, A. Sanjaya, & R. Pinontoan (Eds.), *COVID-19 and Beyond*. Penerbit Andi.

Indini, A., Rijavec, E., Ghidini, M., Bareggi, C., Cattaneo, M., Galassi, B., Gambini, D., & Grossi, F. (2020). Coronavirus Infection and Immune System: An Insight of COVID-19 in Cancer Patients. *Critical Reviews in Oncology/Hematology*, 153(July), 103059.
<https://doi.org/10.1016/j.critrevonc.2020.103059>

Irfannuddin. (2019). *Cara Sistematis Berlatih Meneliti*. Rayyana Komunikasindo.

Jespers, V., Leroy, R., Hulstaert, F., Wyndham, C., Thomas, Montfort, T. Van, Van, P., Damme, & Dogné, J.-M. (2021). *Rapid Review of the Evidence on a Covid-19 Booster Dose After a Primary Vaccination Schedule*.
<https://kce.fgov.be/en/rapid-review-of-the-evidence-on-a-covid-19-booster-dose-after-a-primary-vaccination-schedule>

Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020). - Immunological considerations for COVID-19 vaccine strategies. *Nature Reviews Immunology*, 20(October), 615–632.
<https://doi.org/10.1038/s41577-020-00434-6>

Kadali, R. A. K., Janagama, R., Peruru, S., Gajula, V., Madathala, R. R., Chennaiahgari, N., & Malayala, S. V. (2021). Non Life Threatening Adverse Effects with COVID-19 mRNA-1273 Vaccine: A Randomized, Cross-Sectional Study on Healthcare Workers with Detailed Self-Reported Symptoms. *Journal of Medical Virology*, 93, 4420–4429.

Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A Comprehensive Status Report. *Virus Research*, 288(July), 198114.
<https://doi.org/10.1016/j.virusres.2020.198114>

Kemenkes, ITAGI, UNICEF, & WHO. (2020). *Survei Penerimaan Vaksin COVID-19 di Indonesia*.
<https://www.unicef.org/indonesia/id/coronavirus/laporan/survei-penerimaan-vaksin-covid-19-di-indonesia>

Klein, S. L., & Flanagan, K. L. (2016). Sex Differences in Immune Responses. *Nature Reviews Immunology*, 16(10), 626–638.
<https://doi.org/10.1038/nri.2016.90>

- Klok, F. A., Kruip, M. J. H. A., Meer, N. J. M. van der, Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., Paassen, J. van, Stals, M. A. M., Huisman, M. V., & Endeman, H. (2020). Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. *Thrombosis Research*, 191(January), 56. <https://doi.org/10.1016/j.thromres.2020.04.032>
- Klugar, M., Riad, A., Mekhemar, M., Conrad, J., Buchbender, M., Howaldt, H. P., & Attia, S. (2021). Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines Among German Healthcare Workers. *Biology*, 10(8), 1–21. <https://doi.org/10.3390/biology10080752>
- Konstantinidis, T. G., Zisaki, S., Mitroulis, I., Konstantinidou, E., Kontekaki, E. G., Romanidou, G., Karvelas, A., Nanousi, I., Lazidis, L., Cassimos, D., Tsigalou, C., Martinis, G., & Panopoulou, M. (2021). Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2. *Journal of Clinical Medicine*, 10(13), 4–8. <https://doi.org/10.3390/jcm10132842>
- Krammer, F., Srivastava, K., Simon, V., Alshammary, H., Amoako, A., Awawda, M., Beach, K., Bermúdez-González, C. M., Bialak, D., Carreño, J. M., Chernet, R., Eaker, L., Ferreri, E., Floda, D., Gleason, C., Hamburger, J., Jiang, K., Kleiner, G., Jurczynszak, D., ... Wajnberg, A. (2021). Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *MedRxiv*, 1–5. <https://doi.org/10.1101/2021.01.29.21250653>
- Krammer, Florian, Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G., Jurczynszak, D., Matthews, J. C., ... Simon, V. (2021a). Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *The New England Journal of Medicine*, 384(14), 1372–1374. <https://doi.org/10.1056/NEJMC2101667>
- Krammer, Florian, Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G., Jurczynszak, D., Matthews, J. C., ... Simon, V. (2021b). Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine*, 384(14), 1372–1374. https://doi.org/10.1056/NEJMC2101667/SUPPL_FILE/NEJMC2101667_DISCLOSURES.PDF
- Lidiana, E. H., Mustikasari, H., Pradana, K. A., & Permatasari, A. (2020). Gambaran Karakteristik Kejadian Ikutan Pasca Vaksinasi Covid-19 Pada Tenaga Kesehatan Alumni Universitas 'Aisyiyah Surakarta. *Jurnal Ilmiah*

Kesehatan, 19(Mei).

- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., ... Tan, W. (2020). Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. *The Lancet*, 395(10224), 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
- Maragakis, L., & Kelen, G. D. (2021). *COVID Vaccine Side Effects*. Johns Hopkins Medicine. https://www-hopkinsmedicine-org.translate.google/health/conditions-and-diseases/coronavirus/covid-vaccine-side-effects?_x_tr_sl=en&_x_tr_tl=id&_x_tr_hl=id&_x_tr_pto=op,sc
- Menkes. (2021). *Keputusan Menkes No. HK.01.07/MENKES/4638/2021 tentang Petunjuk Teknis Pelaksanaan Vaksinasi dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19) [JDIH BPK RI]*. <https://peraturan.bpk.go.id/Home/Details/171640/keputusan-menkes-no-hk0107menkes46382021>
- Menkes, 2020. (2020). KMK No. HK.01.07/MenKes/413/2020 PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE 2019 (COVID-19). In *MenKes/413/2020* (Vol. 2019). <https://persi.or.id/wp-content/uploads/2020/03/kmk2472020.pdf>
- Miller, E., & Wodi, A. P. (2021). *General Best Practice Guidance for Immunization*. Centers of Disease Control and Prevention. <https://www.cdc.gov/vaccines/pubs/pinkbook/genrec.html>
- Moore, J. P., & Offit, P. A. (2021). SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. *JAMA - Journal of the American Medical Association*, 325(9), 821–822. <https://doi.org/10.1001/jama.2021.1114>
- Norfai. (2019). *Statistik Non-Parametrik untuk Bidang Kesehatan (Teoritis, Sistematis, dan Adaptif)*. Lakeisha.
- Parés-Badell, O., Martínez-Gómez, X., Pinós, L., Borrás-Bermejo, B., Uriona, S., Otero-Romero, S., Rodrigo-Pendás, J. Á., Cossio-Gil, Y., Agustí, A., Aguilera, C., & Campins, M. (2021). Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. *Vaccines*, 9(12), 3–11. <https://doi.org/10.3390/vaccines9121463>
- Pemda DIY. (2021). *Data Terkait COVID-19 di D.I. Yogyakarta*. Pemerintah Daerah DIY. <https://corona.jogjaprovg.go.id/data-statistik>
- Prihatin, I. U. (2022). *Komnas: Persentase KIPI Tertinggi Terjadi pada Vaksin*

Moderna / merdeka.com. Merdeka.Com.
<https://www.merdeka.com/peristiwa/komnas-persentase-kipti-tertinggi-terjadi-pada-vaksin-moderna.html>

Public Health Ontario. (2022). *Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to February 27, 2022*. file:///C:/Users/DELL/Downloads/Adverse Events Following Immunization (AEFIs) COVID-19 in Ontoro.pdf

Qi, H., Xiao, S., Shi, R., Ward, M. P., Chen, Y., Tu, W., Su, Q., Wang, W., Wang, X., & Zhang, Z. (2020). COVID-19 Transmission in Mainland China is Associated with Temperature and Humidity: A Time-Series Analysis. *Science of the Total Environment*, 728, 138778. <https://doi.org/10.1016/j.scitotenv.2020.138778>

Rahmadhona, D., Sahidu, M. G., & Zulkarnaen, D. A. (2022). Sosialisasi Kejadian Ikutan Pasca Imunisasi Vaksin COVID-19 di Rumah Sakit Universitas Mataram. *Jurnal PEPADU*, 3(1), 56–59.

Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021). Prevalence of COVID-19 Vaccine Side Effects Among Healthcare Workers in the Czech Republic. *Journal of Clinical Medicine*, 10(7). <https://doi.org/10.3390/jcm10071428>

Romadhan, A., Pratama, L., Magglin, C., Jufrie, H., Fatimah, N., Khairul, M., & Bakhtiar, R. (2022). *Karakteristik Kejadian Ikutan Pasca Imunisasi Moderna pada Tenaga Kesehatan*. 9(1), 1–13.

Rosenblum, H. G., Gee, J., Liu, R., Marquez, P. L., Zhang, B., Strid, P., Abara, W. E., Mcneil, M. M., Myers, T. R., Hause, A. M., Su, J. R., Markowitz, L. E., Shimabukuro, T. T., & Shay, D. K. (2020). *Safety of mRNA Vaccines Administered During the Initial 6 Months of the US COVID-19 Vaccination Programme: An Observational Study of Reports to the Vaccine Adverse Event Reporting System and v-safe*. January.

Rutakirwa, T. (2021). *Understanding Coronavirus (COVID-19)*. Lulu.com. https://www.google.co.id/books/edition/Understanding_Coronavirus_COVID_19/sFA3EAAAQBAJ?hl=id&gbpv=0

Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O. (2021). Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination. *International Journal of Infectious Diseases*, 111, 219–226. <https://doi.org/10.1016/j.ijid.2021.08.013>

Salvador, A., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2019). An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines. *Journal of Drug Delivery*, 2011, 1–18.

<https://doi.org/10.1155/2011/181646>

Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., Kerepesi, C., Yim, S. H., Fedichev, P. O., & Gladyshev, V. N. (2020). COVID-19 is an Emergent Disease of Aging. *Aging Cell*, *19*(10), 1–10. <https://doi.org/10.1111/accel.13230>

SATGAS COVID-19. (2021a). *Informasi tentang KIPI atau Reaksi Setelah Vaksinasi COVID-19*. Satuan Gugus Tugas Penanganan COVID-19. <https://kipi.covid19.go.id/>

SATGAS COVID-19. (2021b). *Laporan Terbaru CDC Mengenai Efek Samping Vaksin COVID-19*. Satuan Gugus Tugas Penanganan COVID-19. <https://covid19.go.id/p/berita/laporan-terbaru-cdc-mengenai-efek-samping-vaksin-covid-19>

SATGAS COVID-19. (2021c). *Peta Sebaran Kasus COVID-19*. Satuan Tugas Penanganan COVID-19. <https://covid19.go.id/peta-sebaran>

Siregar, M. H., Susanti, R., Indriawati, R., Panma, Y., Hanaruddin, D. Y., Adhiwijaya, A., Akbar, H., Agustiawan, Nugraha, D. P., & Renaldi, R. (2021). *Metodologi Penelitian Kesehatan*. Yayasan Penerbit Muhammad Zaini.

Soysal, A., Gönüllü, E., Karabayır, N., Alan, S., Atıcı, S., Yıldız, İ., Engin, H., Çivilibal, M., & Karaböcüoğlu, M. (2021). Comparison of Immunogenicity and Reactogenicity of Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Previously SARS-CoV-2 Infected and Uninfected Health Care Workers. *Human Vaccines and Immunotherapeutics*, *17*(11), 3876–3880. <https://doi.org/10.1080/21645515.2021.1953344>

Ssentongo, P., Ssentongo, A. E., Heilbrunn, E. S., Ba, D. M., & Chinchilli, V. M. (2020). Association of Cardiovascular Disease and 10 Other Pre-existing Comorbidities with COVID-19 Mortality: A Systematic Review and Meta-analysis. *PLoS ONE*, *15*(8 August), 1–16. <https://doi.org/10.1371/journal.pone.0238215>

Stamatatos, L., Czartoski, J., Wan, Y. H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., Feng, J., Mize, G., De Rosa, S. C., Finzi, A., Lemos, M. P., Cohen, K. W., Moodie, Z., McElrath, M. J., & McGuire, A. T. (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. In *Science* (Vol. 372, Issue 6549). <https://doi.org/10.1126/science.abg9175>

Sugiyono. (2019). *Metodologi Penelitian Kuantitatif*. Alfabeta.

Supangat, Sakinah, E. N., Nugraha, M. Y., Qodar, T. S., Mulyono, B. W., & Tohari, A. I. (2021). COVID-19 Vaccines Programs: Adverse Events Following

Immunization (AEFI) Among Medical Clerkship Student in Jember, Indonesia. *Digital Repository Universitas Jember, September 2019*, 1–7.

- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yunihastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, 7(1), 45. <https://doi.org/10.7454/jpdi.v7i1.415>
- Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal Coagulation Parameters are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. *Journal of Thrombosis and Haemostasis*, 18(4), 844–847. <https://doi.org/10.1111/jth.14768>
- Tejedor Vaquero, S., de Campos-Mata, L., Ramada, J. M., Díaz, P., Navarro-Barriuso, J., Ribas-Llaurado, C., Rodrigo Melero, N., Carolis, C., Cerutti, A., Gimeno, R., & Magri, G. (2021). The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. *Frontiers in Immunology*, 12(September), 1–9. <https://doi.org/10.3389/fimmu.2021.737083>
- Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., Groom, H. C., Dunnigan, K., Odean, M. J., Hegmann, K., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., ... Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *New England Journal of Medicine*, 385(4), 320–329. <https://doi.org/10.1056/nejmoa2107058>
- Tissot, N., Brunel, A., Bozon, F., Rosolen, B., & Chirouze, C. (2021). Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. *Journal Vaccine, January*.
- Tre-Hardy, M., Cupaiolo, R., Papeux, E., Wilmet, A., Horeanga, A., Antoine-Moussiaux, T., Vecchia, A. Della, Beukinga, I., Vekemans, M., & Blairon, L. (2021). Reactogenicity, Safety and Antibody Response, After One and Two Doses of mRNA-1273 in Seronegative and Seropositive Healthcare Workers. *Journal of Infection*, 83(January), 237–279.
- Vassallo, A., Shajahan, S., Harris, K., Hallam, L., Hockham, C., Womersley, K., Woodward, M., & Sheel, M. (2021). Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain. *Frontiers in Global Women's Health*, 2(November). <https://doi.org/10.3389/fgwh.2021.761511>
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng,

- Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - Journal of the American Medical Association*, 323(11), 1061–1069. <https://doi.org/10.1001/jama.2020.1585>
- WHO. (2020a). Rational Use Of Personal Protective Equipment COVID-19 - Interim Guidance. *World Health Organization*, 2019(February), 1–7. https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf
- WHO. (2020b). *WHO Director-General's Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020*. WHO. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
- WHO. (2021a). *Rekomendasi Interim untuk Penggunaan Vaksin COVID-19 Moderna mRNA-1273*. 7, 1–8.
- WHO. (2021b). *Weekly Epidemiological Update on COVID-19 - 9 November 2021*. WHO. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---9-november-2021>
- WHO. (2022). *The Moderna COVID-19 (mRNA-1273) Vaccine: What You Need to Know*. World Health Organisation. <https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know>
- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - Journal of the American Medical Association*, 324(8), 782–793. <https://doi.org/10.1001/jama.2020.12839>
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., & Wang, F. S. (2020). Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. *The Lancet Respiratory Medicine*, 8(4), 420–422. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X)
- Yuliana, Y. (2020). Corona Virus Diseases (COVID-19): Sebuah Tinjauan Literatur. *Wellness And Healthy Magazine*, 2(1), 187–192. <https://doi.org/10.30604/well.95212020>
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in

China, 2019. *New England Journal of Medicine*, 382(8), 727–733.
<https://doi.org/10.1056/nejmoa2001017>

Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020). Single-Cell RNA-Seq Data Analysis on the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection. *Advances in Experimental Medicine and Biology*, 1179(2), 185–192.
https://doi.org/10.1007/978-981-13-9151-4_5

UNIVERSITAS JENDERAL ACHMAD YANI YOGYAKARTA
PERPUSTAKAAN